[go: up one dir, main page]

PE20251586A1 - Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos - Google Patents

Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos

Info

Publication number
PE20251586A1
PE20251586A1 PE2025000776A PE2025000776A PE20251586A1 PE 20251586 A1 PE20251586 A1 PE 20251586A1 PE 2025000776 A PE2025000776 A PE 2025000776A PE 2025000776 A PE2025000776 A PE 2025000776A PE 20251586 A1 PE20251586 A1 PE 20251586A1
Authority
PE
Peru
Prior art keywords
slc6a19
independently
pharmaceutically acceptable
tautomer
stereoisomer
Prior art date
Application number
PE2025000776A
Other languages
English (en)
Inventor
Jennifer Pitzen
Maximiliano De La Higuera Macias
Nicole Cooper
Christopher Joseph Sinz
Patrick Sang Tae Lee
Jessica Wahlers
Nathan Fastman
Christos Tzitzilonis
Jr David John Morgans
Yuxi Liu
Adam Neil Reid
Chris Ziebenhaus
Alexander Wayne Schammel
Caleb Henry Karmel
Kevin Mellem
Original Assignee
Maze Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maze Therapeutics Inc filed Critical Maze Therapeutics Inc
Publication of PE20251586A1 publication Critical patent/PE20251586A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invencion se refiere a compuestos de formula (II): o un estereoisomero o tautomero del mismo, o una sal farmaceuticamente aceptable de cualquiera de los anteriores, en donde m es un numero entero de 1 a 4; n es un numero entero de 0 a 4; X es -O-, -S-, -N(H)-, entre otros; R1 es -NH-, -O-, o -S-; R2 es H; R3, R5, R7 son cada uno independientemente alquiloC1-6, haloalquiloC1-6, entre otros; R6 y R9 son cada uno independientemente H o halo; R8 es alcoxiC1-6, cicloalquiloC3-10, entre otros; R10 es, independientemente en cada aparicion, H o D; R11a y R11b son cada uno independientemente en cada aparicion, H o alquiloC1-6, entre otros. Tambien se refiere a un proceso para preparar dicho compuesto; asi como a una composicion farmaceutica que comprende (i) el compuesto, un estereoisomero o tautomero del mismo, o una sal farmaceuticamente aceptable de cualquiera de ellos y (ii) uno o mas excipientes farmaceuticamente aceptables. Una cantidad eficaz del compuesto, de su estereoisomero o tautomero del mismo, o de una sal farmaceuticamente aceptable, o bien de una composicion farmaceutica que los contenga, permite inhibir al miembro 19 de la familia de portadores de solutos 6A (SLC6A19). Esto posibilita, al administrarse a un individuo que lo necesita, el tratamiento de una enfermedad, trastorno o afeccion mediada por SLC6A19, como la fenilcetonuria (PKU), la enfermedad renal cronica (CKD), entre otros.
PE2025000776A 2022-10-12 2023-10-11 Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos PE20251586A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263415590P 2022-10-12 2022-10-12
US202363456403P 2023-03-31 2023-03-31
US202363532327P 2023-08-11 2023-08-11
PCT/US2023/076625 WO2024081748A2 (en) 2022-10-12 2023-10-11 Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20251586A1 true PE20251586A1 (es) 2025-06-16

Family

ID=90670219

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025000776A PE20251586A1 (es) 2022-10-12 2023-10-11 Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos

Country Status (14)

Country Link
US (1) US20240199546A1 (es)
EP (1) EP4601635A2 (es)
JP (1) JP2025534664A (es)
KR (1) KR20250103814A (es)
CN (1) CN120693157A (es)
AU (1) AU2023361174A1 (es)
CL (1) CL2025001057A1 (es)
CO (1) CO2025005880A2 (es)
CR (1) CR20250176A (es)
IL (1) IL320191A (es)
MX (1) MX2025004221A (es)
PE (1) PE20251586A1 (es)
TW (1) TW202432108A (es)
WO (1) WO2024081748A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025196623A1 (en) * 2024-03-21 2025-09-25 Pfizer Inc. Indole analogs
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
US20250346567A1 (en) * 2024-05-13 2025-11-13 Pfizer Inc. Substituted pyridine and phenyl compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009028629A1 (ja) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US9567339B2 (en) * 2013-06-26 2017-02-14 Abbvie Inc. Primary carboxamides as BTK inhibitors
CA2954751C (en) * 2014-08-08 2023-01-17 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection

Also Published As

Publication number Publication date
CO2025005880A2 (es) 2025-05-29
AU2023361174A1 (en) 2025-05-01
MX2025004221A (es) 2025-05-02
US20240199546A1 (en) 2024-06-20
WO2024081748A2 (en) 2024-04-18
CR20250176A (es) 2025-06-25
IL320191A (en) 2025-06-01
CL2025001057A1 (es) 2025-08-01
EP4601635A2 (en) 2025-08-20
CN120693157A (zh) 2025-09-23
TW202432108A (zh) 2024-08-16
KR20250103814A (ko) 2025-07-07
WO2024081748A3 (en) 2024-05-30
JP2025534664A (ja) 2025-10-17

Similar Documents

Publication Publication Date Title
PE20251586A1 (es) Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
PE20221457A1 (es) Degradadores de moleculas pequenas de helios y procedimientos de uso
AR041055A1 (es) Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto
AR081261A1 (es) Metodos para tratar afecciones virales
PE20140405A1 (es) Terapias combinadas para malignidades hematologicas
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
UY28192A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan.
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20252677A1 (es) Amidas de azolipiridina piridazinona como inhibidores de sos1
CR20190261A (es) Inhibidores de la tirosina quinasa de bruton
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
PE20250603A1 (es) Inhibidores de apol1 y metodos de uso
CO2021017202A2 (es) Compuestos tricíclicos
PE20251587A1 (es) 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1
AR124189A1 (es) Compuestos y procedimientos de uso de los mismos
MX2021009206A (es) Terapias contra el cancer.
PE20251389A1 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2022011240A (es) Azálidos de urea inmunomoduladores.
AR038094A1 (es) Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica
MX2021008386A (es) Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b.
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias